Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $32.38
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has been assigned a consensus rating of “Hold” from the eight analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have issued a buy recommendation on the company. […]
More Stories
Pan American Silver (TSE:PAAS) Price Target Raised to C$45.00
Pan American Silver (TSE:PAAS – Get Free Report) had its price objective lifted by equities researchers at National Bankshares from...
Brookfield Renewable Partners (NYSE:BEP) Given New $40.00 Price Target at CIBC
Brookfield Renewable Partners (NYSE:BEP – Get Free Report) (TSE:BEP) had its target price increased by equities researchers at CIBC from...
Stock Analysts’ Price Target Changes for January 9th (ALA, ATZ, AYA, AYI, BEP, BNS, CXB, EDV, ENB, GBX)
Stock Analysts’ price target changes for Thursday, January 9th: AltaGas (TSE:ALA) had its price target increased by CIBC from C$40.00...
FDA Mandates Nerve Damage Warnings for 2 RSV Vaccines
By Naveen Athrappully The U.S. Food and Drug Administration (FDA) ordered two respiratory syncytial virus (RSV) vaccine manufacturers to include...
Rep. Virginia Foxx Sells Off Shares of Energy Transfer LP (NYSE:ET)
Representative Virginia Foxx (R-North Carolina) recently sold shares of Energy Transfer LP (NYSE:ET). In a filing disclosed on January 06th,...
Anterix (NASDAQ:ATEX) Reaches New 12-Month Low – Should You Sell?
Anterix Inc. (NASDAQ:ATEX – Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low...